GlassScriptPhysician profile
Reena S Shah
NPI 1649305863
$179,865.49
in general payments reported to CMS, 2019-2025
12 companies · $6,974 in 2025
The $6,974 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $68K · 2021: $33K · 2022: $40K · 2023: $9,354 · 2024: $5,728 · 2025: $6,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $1,525 · Food and Beverage: $1,108 · Travel and Lodging: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,293.75 |
| Consulting Fee | $1,525.00 |
| Food and Beverage | $1,108.29 |
| Travel and Lodging | $128.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $117,493.09 | 2019-2024 | Amyvid |
| Abbvie INC. | $25,728.22 | 2022-2025 | Ubrelvy, Qulipta |
| Biohaven Pharmaceutical Holding Company LTD. | $20,219.97 | 2022 | |
| Lundbeck LLC | $7,981.52 | 2020-2024 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $6,663.77 | 2021 | |
| Pfizer INC. | $1,525.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $111.62 | 2024 | Sotyktu |
| Genentech USA, INC. | $80.80 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $48.51 | 2023 | Dysport |
| Depuy Synthes Sales INC. | $12.99 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.